Enovis (NYSE:ENOV) Downgraded to Hold Rating by Wall Street Zen

Wall Street Zen lowered shares of Enovis (NYSE:ENOV) from a buy rating to a hold rating in a research note issued to investors on Saturday.

ENOV has been the topic of several other research reports. BTIG Research boosted their price target on Enovis from $39.00 to $40.00 and gave the stock a “buy” rating in a research report on Thursday. UBS Group reiterated a “buy” rating and set a $51.00 price objective (up from $50.00) on shares of Enovis in a research note on Tuesday, July 28th. Evercore set a $32.00 target price on shares of Enovis in a research note on Monday, July 6th. Wells Fargo & Company lowered their target price on shares of Enovis from $40.00 to $39.00 and set an “overweight” rating on the stock in a report on Friday. Finally, William Blair started coverage on shares of Enovis in a research report on Friday, April 17th. They set an “outperform” rating on the stock. Eight research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $42.00.

Enovis Trading Up 1.4%

Enovis stock opened at $26.68 on Friday. The firm has a 50-day moving average of $24.62 and a 200-day moving average of $23.97. Enovis has a one year low of $19.14 and a one year high of $34.28. The company has a debt-to-equity ratio of 0.84, a current ratio of 1.98 and a quick ratio of 1.05. The company has a market cap of $1.54 billion, a price-to-earnings ratio of -1.39 and a beta of 1.34.

Enovis (NYSE:ENOV) last released its earnings results on Thursday, August 6th. The company reported $0.90 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.85 by $0.05. Enovis had a positive return on equity of 12.03% and a negative net margin of 47.96%.The business had revenue of $582.78 million for the quarter, compared to the consensus estimate of $581.84 million. During the same quarter in the previous year, the business earned $0.79 earnings per share. Enovis’s quarterly revenue was up 3.2% on a year-over-year basis. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. On average, equities analysts expect that Enovis will post 3.12 earnings per share for the current fiscal year.

Insider Activity at Enovis

In related news, insider Oliver Engert acquired 1,200 shares of the firm’s stock in a transaction on Thursday, June 11th. The shares were purchased at an average cost of $21.62 per share, for a total transaction of $25,944.00. Following the completion of the acquisition, the insider directly owned 51,840 shares in the company, valued at approximately $1,120,780.80. This trade represents a 2.37% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders have acquired 4,200 shares of company stock valued at $92,084 in the last 90 days. 2.90% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Arax Advisory Partners acquired a new stake in Enovis during the fourth quarter worth approximately $29,000. EverSource Wealth Advisors LLC boosted its holdings in shares of Enovis by 125.4% during the second quarter. EverSource Wealth Advisors LLC now owns 1,271 shares of the company’s stock worth $40,000 after acquiring an additional 707 shares during the period. Danske Bank A S acquired a new position in shares of Enovis in the third quarter valued at approximately $64,000. iSAM Funds UK Ltd bought a new position in shares of Enovis during the third quarter worth approximately $80,000. Finally, Brown Brothers Harriman & Co. acquired a new stake in Enovis during the 3rd quarter worth approximately $90,000. Institutional investors and hedge funds own 98.45% of the company’s stock.

Key Enovis News

Here are the key news stories impacting Enovis this week:

• Positive Sentiment: Enovis reported second-quarter adjusted earnings of $0.90 per share, above the $0.85 analyst consensus and up from $0.79 a year earlier. Revenue of $582.8 million was also slightly ahead of estimates, while sales increased 3.2% year over year. Enovis Q2 Earnings and Revenue Estimates
• Positive Sentiment: Management reaffirmed its full-year 2026 outlook, including revenue of approximately $2.3 billion to $2.4 billion and adjusted EPS guidance of $3.52 to $3.73. Reconstructive sales were a relative bright spot, rising 8% on a reported basis and 6% organically. Enovis Announces Second Quarter 2026 Results
• Positive Sentiment: BTIG Research raised its price target from $39 to $40 and maintained a Buy rating, implying substantial potential upside from recent trading levels. BTIG Research Price Target
• Neutral Sentiment: Wells Fargo lowered its price target modestly from $40 to $39 but retained an Overweight rating, indicating continued long-term confidence despite near-term concerns. Wells Fargo Price Target
• Negative Sentiment: The market reaction was negative because Enovis’ second-quarter performance was characterized as “softer than expected.” Although revenue and EPS exceeded published estimates, investors appear focused on the relatively modest 3% reported sales growth and the lack of an upward guidance revision. Enovis Shares Drop After Second-Quarter Earnings
• Negative Sentiment: Enovis continues to report a deeply negative GAAP net margin, which may reinforce investor concerns about profitability and execution even though adjusted earnings improved. Enovis Q2 2026 Earnings Call Transcript

About Enovis

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.